Indications for Neoadjuvant Chemotherapy

Primary Indications by Cancer Type

• The American College of Surgeons recommends neoadjuvant chemotherapy for locally advanced breast cancer (stage II-III) requiring tumor downstaging to enable breast-conserving surgery or achieve operability 1, 2
• The American Society of Clinical Oncology suggests that any breast cancer patient who would receive adjuvant chemotherapy can be offered neoadjuvant therapy as an equivalent option 1
• The National Comprehensive Cancer Network recommends neoadjuvant chemotherapy with dual HER2 blockade (trastuzumab and pertuzumab) plus taxanes for HER2-positive stage II-III disease 1
• The European Society for Medical Oncology states that triple-negative breast cancer benefits from neoadjuvant chemotherapy with higher pathologic complete response rates, particularly when platinum compounds are added for BRCA1/2 mutation carriers 2
• The American Cancer Society indicates that locally advanced gastric cancer (cT3-4aN+M0, stage cIII) should receive neoadjuvant chemotherapy with FOLFOX, SOX, or FLOT regimens 3
• The National Cancer Institute recommends FLOT as standard perioperative chemotherapy (4 preoperative cycles) for oesophageal adenocarcinoma 4
• The American Joint Committee on Cancer suggests that serosal infiltrating tumors, bulky metastatic nodes, or Borrmann type 4 cancers should receive neoadjuvant chemotherapy to increase R0 resectability rates 5
• The European Society of Surgical Oncology recommends neoadjuvant chemotherapy for gastric cancer T≥3 and/or with metastatic nodes on preoperative workup 5
• The American Urological Association states that muscle-invasive bladder cancer should receive neoadjuvant cisplatin-based chemotherapy before cystectomy 6

Treatment Selection Algorithm

• The American Society of Clinical Oncology recommends that if breast-conserving surgery is not feasible or would result in poor cosmesis, neoadjuvant therapy is preferred 1
• The National Comprehensive Cancer Network suggests that if breast-conserving surgery is feasible with acceptable cosmesis, neoadjuvant therapy is optional but can still be offered 1
• The European Society for Medical Oncology indicates that if tumor is locally advanced or inflammatory, neoadjuvant therapy is mandatory 1, 2

Standard Chemotherapy Regimens

• The American College of Surgeons recommends anthracycline and taxane-based regimens (sequential or combination) as the backbone for breast cancer 1
• The National Cancer Institute states that at least 6 cycles over 4-6 months should be planned and delivered preoperatively for breast cancer 1
• The European Society for Medical Oncology suggests that FLOT (fluorouracil, leucovorin, oxaliplatin, docetaxel) is a standard perioperative chemotherapy regimen for gastric and gastroesophageal cancer 4
• The American Urological Association recommends a minimum of 3 cycles of cisplatin-based combination (ddMVAC, gemcitabine plus cisplatin, or CMV) for bladder cancer 6

Critical Timing Considerations

• The American Society of Clinical Oncology recommends that surgery should occur 2-4 weeks after completion of neoadjuvant chemotherapy 1
• The National Comprehensive Cancer Network suggests that all planned chemotherapy should be delivered preoperatively without dividing into preoperative and postoperative periods, regardless of response magnitude 2

Pre-Treatment Requirements

• The American College of Surgeons recommends that core biopsy is mandatory before starting neoadjuvant therapy to confirm invasive cancer and obtain predictive markers (histological subtype, tumor grading, ER/PR status, HER2 status) 1
• The National Cancer Institute states that referral to breast surgeon and radiation oncologist is necessary before initiating neoadjuvant therapy 1
• The European Society for Medical Oncology suggests that multidisciplinary team discussion is necessary for all locally advanced cases to determine individualized treatment plans 3, 5

Common Pitfalls to Avoid

• The American Society of Clinical Oncology recommends that neoadjuvant therapy should not be withheld based solely on chronological age 2
• The National Comprehensive Cancer Network suggests that neoadjuvant endocrine therapy should not be used in patients who are candidates for chemotherapy unless specific contraindications exist 2
• The European Society for Medical Oncology indicates that carboplatin should not be used instead of cisplatin in perioperative bladder cancer treatment 6

Survival and Outcome Data

• The American College of Surgeons states that meta-analyses demonstrate no difference in survival or overall disease progression between neoadjuvant and adjuvant therapy 1

Neoadjuvant vs Adjuvant Chemotherapy in Breast Cancer: Comparative Outcomes

Survival and Distant Metastases: No Difference

• The National Comprehensive Cancer Network recommends that neoadjuvant chemotherapy produces identical disease-free survival and overall survival compared to adjuvant chemotherapy, with high strength of evidence 7, 8
• The risk of distant metastases is equal between neoadjuvant and adjuvant approaches, establishing neoadjuvant treatment as a standard option rather than an inferior alternative, according to the National Comprehensive Cancer Network 7
• The NSABP B-18 trial confirmed no disease-specific survival advantage for preoperative chemotherapy over postoperative adjuvant chemotherapy in stage II tumors, with moderate strength of evidence 7, 8

Breast-Conserving Surgery: Substantial Increase

• Neoadjuvant chemotherapy increases breast conservation rates by more than 50% compared to upfront surgery, with moderate strength of evidence, according to the British Journal of Cancer 9
• The NSABP B-18 trial documented significantly higher breast conservation rates after preoperative chemotherapy, with high strength of evidence, as recommended by the National Comprehensive Cancer Network 8

Local Recurrence: Higher Risk Attributed to Breast Conservation

• The critical nuance is that the increased local recurrence risk is not due to neoadjuvant chemotherapy itself, but rather to the increased use of breast-conserving surgery that neoadjuvant therapy enables, with moderate strength of evidence, according to the British Journal of Cancer and the National Comprehensive Cancer Network 8, 9
• The higher local recurrence risk compared to primary mastectomy reflects the inherent difference between breast conservation and mastectomy, not a failure of neoadjuvant timing, with moderate strength of evidence, as reported in the British Journal of Cancer 9

Critical Selection Factors for Breast Conservation After Neoadjuvant Therapy

• Contraindications to breast conservation after neoadjuvant therapy include inflammatory disease, incomplete resolution of skin involvement, and standard contraindications to breast conservation, as recommended by the National Comprehensive Cancer Network, with high strength of evidence 10
• For patients with skin/chest wall involvement before neoadjuvant therapy, breast conservation may be performed only in carefully selected patients based on multidisciplinary assessment of local recurrence risk, with moderate strength of evidence, according to the National Comprehensive Cancer Network 10

Practical Algorithm for Treatment Selection

• If breast-conserving surgery is not initially feasible or would result in poor cosmesis, neoadjuvant therapy is the preferred approach, and percutaneously placed clips into the tumor under imaging guidance before starting chemotherapy are essential for accurate resection of the original tumor bed, with high strength of evidence, as recommended by the National Comprehensive Cancer Network 8
• After neoadjuvant therapy response, if tumor responds adequately and breast conservation requirements are fulfilled, lumpectomy is oncologically safe, with moderate strength of evidence, according to the National Comprehensive Cancer Network 8

Common Pitfalls to Avoid

• Do not assume neoadjuvant therapy increases systemic recurrence risk—distant metastases rates are identical to adjuvant therapy, with high strength of evidence, as reported by the National Comprehensive Cancer Network 7
• Do not attribute higher local recurrence to neoadjuvant timing—the increase reflects the shift from mastectomy to breast conservation, with moderate strength of evidence, according to the British Journal of Cancer and the National Comprehensive Cancer Network 8, 9
• Do not perform breast conservation in patients with inflammatory disease or incomplete skin involvement resolution after neoadjuvant therapy, with high strength of evidence, as recommended by the National Comprehensive Cancer Network 10
• Do not fail to place tumor localization clips before starting neoadjuvant therapy—this is essential for accurate resection of the original tumor bed, with high strength of evidence, according to the National Comprehensive Cancer Network 8